Autor: Kristina Friedland

Yokogawa grant together with Kristina Endres and Scotland-RLP Life Science Research Funding

Yokogawa provides a Single Cellome™ System SS2000 (one of eight world wide) to the Endres and Friedland lab to investigate mitochondrial function/dysfunction in Alzheimer disease and aging. We are so excited to work with this elaborated confocal which is allows to prep cell organelles from single cells.

Together with Prof. Albena Dinkova-Kostova from the University of Dundee, we received funding from the Scotland-RLP Life Science Research Alliance. One of Albenas PhD students, Miro Novak, will investigate the effects of novel NRF-2 ligands in the Friedland lab. We are looking forward to this collaboration. Check out Albenas paper in Nature Reviews Drug Discovery about the therapeutical potential of NRF-2 ligands.

Veröffentlicht am | Veröffentlicht in Allgemein, News

Peer reviewed publications

  1. Schulz C., Fritz N., Sommer T., Krofta K., Friedland K., Pischetsrieder M. Activation of membrane-located Ca2+ channels by hop beta acids and their tricyclic transformation products. (2018) Food Chem. 252:215-227. doi: 10.1016/j
  2. Beckervordersandforth R., Ebert B., Schäffner I., Moss J., Fiebig C., Shin J., Moore D.L., Ghosh L., Trinchero M.F., Stockburger C., Friedland K., Steib K., von Wittgenstein J., Keiner S., Redecker C., Hölter S.M., Xiang W., Wurst W., Jagasia R., Schinder A.F., Ming G.L., Toni N., Jessberger S., Song H., Lie D.C. Role of Mitochondrial Metabolism in the Control of Early Lineage Progression and Aging Phenotypes in Adult Hippocampal Neurogenesis. (2017) Neuron. 93(6):1518. doi: 10.1016/j.neuron.2017.03.008.
  3. Möller D., Banerjee A., Uzuneser T.C., Skultety M., Huth T., Plouffe B., Hübner H., Alzheimer C., Friedland K., Müller C.P., Bouvier M., Gmeiner P. Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure. (2017) J Med Chem. 60(7):2908-2929. doi: 10.1021/acs.jmedchem.6b01857.
  4. Menges S., Minakaki G., Schaefer P.M., Meixner H., Prots I., Schlötzer-Schrehardt U., Friedland K., Winner B., Outeiro T.F., Winklhofer K.F., von Arnim C.A., Xiang W., Winkler J., Klucken J. Alpha-synuclein prevents the formation of spherical mitochondria and apoptosis under oxidative stress. (2017) Sci Rep. 7:42942. doi: 10.1038/srep42942.
  5. Lieb S, Littmann T, Plank N, Felixberger J, Tanaka M, Schäfer T, Krief S, Elz S, Friedland K, Bernhardt G, Wegener J, Ozawa T, Buschauer A. Label-free versus conventional cellular assays: Functional investigations on the human histamine H1 receptor. (2016) Pharmacol Res. 114:13-26. doi: 10.1016/j.phrs.
  6. Wolf C:, Pauly A., Mayr A., Grömer T., Lenz B., Kornhuber J., Friedland K. Pharmacist-Led Medication Reviews to Identify and Collaboratively Resolve Drug-Related Problems in Psychiatry - A Controlled, Clinical Trial. (2015) PLOS One 10(11):e0142011
  7. Denzer I., Münch G., Pischetsrieder M., Friedland K. S-Allyl-L-cysteine and isoliquiritigenin improve mitochondrial function in cellular models of oxidative and nitrosative stress. (2016) Food Chem. 194:843-8. doi:10.1016.
  8. Pauly A., Wolf C., Mayr A., Lenz B., Kornhuber J., Friedland K. Effect of a multi-dimensional and inter-sectoral intervention on the adherence of psychiatric patients. (2015) PLOS One 10(10):e0139302
  9. Stockburger C., Miano D., Baeumlisberger M., Pallas T., Arrey T.N., Karas M., Friedland K*., Müller W.E. A mitochondrial role of SV2a protein in aging and Alzheimer’s disease – studies with Levetiracetam. (2016) JAD 50(1):201-15.doi:10.3233/JAD-150687  *corresponding author
  10. Wolf C:, Pauly A., Mayr A., Grömer T., Lenz B., Kornhuber J., Friedland K. Pharmacist-Led Medication Reviews to Identify and Collaboratively Resolve Drug-Related Problems in Psychiatry - A Controlled, Clinical Trial. PLOS One (2015) 10(11):e0142011
  11. Denzer I., Münch G., Pischetsrieder M., Friedland K. S-Allyl-L-cysteine and isoliquiritigenin improve mitochondrial function in cellular models of oxidative and nitrosative stress. (2015) Food Chem. accepted.
  12. Schmiedel K., Mayr A., Fießler C., Schlager H., Friedland K. Effects of the lifestyle intervention program GLICEMIA in people at risk for type 2 diabetes: a cluster-randomized controlled trial. Diabetes Care (2015) 38(5):937-9.
  13. Stockburger C., Gold V.A., Pallas T., Kolesova N., Miano D., Leuner K., Müller WE. A Cell Model for the Initial Phase of Sporadic Alzheimer's Disease. J Alzheimers Dis. (2014) 42(2):395-411.*corresponding author
  14. Möller D., Kling R.C., Skultety M., Leuner K., Hübner H., Gmeiner P. Functionally selective  dopamine D₂, D₃ receptor partial agonists. J Med Chem. (2014) 57(11):4861-75.
  15. Eckmann J., Clemens L.E., Eckert S.H., Hagl S., Yu-Taeger L., Bordet T., Pruss R.M., Müller W.E., Leuner K., Nguyen H.P., Eckert G.P. Mitochondrial Membrane Fluidity is Consistently Increased in Different Models of Huntington Disease: Restorative Effects of Olesoxime. Mol Neurobiol. (2014) 50(1):107-18.
  16. Kandel B.A., Ekins S., Leuner K., Thasler W.E., Harteneck C., Zanger U.M. No activation of human pregnane X receptor by hyperforin-related phloroglucinols. J Pharmacol Exp Ther. (2014) 348(3):393-400.
  17. Stockburger C., Kurz C., Koch K.A., Eckert S.H., Leuner K., Müller W.E. Improvement of mitochondrial function and dynamics by the metabolic enhancer piracetam. Biochem Soc Trans. (2013) 41(5):1331
  18. Rossi D., Pedrali A., Marra A., Pignataro L., Schepmann D., Wünsch B., Ye L., Leuner K., Peviani M., Curti D., Azzolina O., Collina S. Studies on the enantiomers of RC-33 as neuroprotective agents: isolation, configurational assignment, and preliminary biological profile. Chirality. (2013) 25(11):814-22.
  19. Heiser J.H., Schuwald A.M., Sillani G., Ye L., Müller W.E., Leuner K. TRPC6 channel-mediated neurite outgrowth in PC12 cells and hippocampal neurons involves activation of RAS/MEK/ERK, PI3K, and CAMKIV signaling. J Neurochem. (2013) 127(3):303-13.
  20. Prinz M., Parlar S., Bayraktar G., Alptüzün V., Erciyas E., Fallarero A., Karlsson D., Vuorela P., Burek M., Förster C., Turunc E, Armagan G., Yalcin A., Schiller C., Leuner K., Krug M., Sotriffer C.A., Holzgrabe U.1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier. Eur J Pharm Sci. (2013) 49(4):603-13.
  21. Schuwald A.M., Nöldner, M., Wilmes T., Klugbauer N., Leuner K., Müller W.E. Lavender oil – potent anxiolytic properties via modulating voltage dependent channels. PLOS one (2013) 8(4):e59998.*Corresponding author
  22. Schulz K.L., Eckert A., Rhein V., Mai S., Haase W., Reichert A.S., Jendrach M., Müller W.E., Leuner K. A new link to mitochondrial impairment in tauopathies. Mol Neurobiol. (2012) 46(1):205-16.
  23. Leuner K., Schulz K., Schütt T., Pantel J., Prvulovic D., Rhein V., Savaskan E., Czech C., Eckert A., Müller W.E. Peripheral mitochondrial dysfunction in Alzheimer's disease: focus on lymphocytes. Mol Neurobiol. (2012) 46(1):194-204.
  24. Leuner K., Li W., Amaral M.D., Rudolph S., Calfa G., Schuwald A.M., Harteneck C., Inoue T., Pozzo-Miller L. Hyperforin modulates dendritic spine morphology in hippocampal pyramidal neurons by activating Ca(2+) -permeable TRPC6 channels. Hippocampus (2013) 23(1):40-52.
  25. Eckmann J., Eckert S.H., Leuner K., Muller W.E., Eckert G.P. Mitochondria: mitochondrial membranes in brain ageing and neurodegeneration. Int J Biochem Cell Biol. (2013) 45(1):76-80.
  26. Cernescu M., Stark T., Kalden E., Kurz C., Leuner K., Deller T., Göbel M., Eckert G.P., Brutschy B. Laser-induced liquid bead ion desorption mass spectrometry: an approach to precisely monitor the oligomerization of the β-amyloid peptide. Anal Chem. (2012) 84(12):5276-84.
  27. Eckert S.H., Eckmann J., Renner K., Eckert G.P., Leuner K., Müller W.E. Dimebon ameliorates amyloid-β induced impairments of mitochondrial form and function. J Alzheimers Dis. (2012) 31(1):21-32.
  28. Leuner K., Schütt T., Kurz C., Eckert S.H., Schiller C., Occhipinti A., Mai S., Jendrach M., Eckert G.P., Kruse S.E., Palmiter R.D., Brandt U., Dröse S., Wittig I., Willem M., Haass C., Reichert A.S., Müller W.E. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid Redox Signal. (2012) 16(12):1421-33.
  29. Leuner K., Kraus M., Wölfe U., Beschmann H., Boehncke W.H., Schempp C.M., Müller W.E. Reduced TRPC channel expression in psoriatic keratinocytes leads to impaired differentiation and enhanced proliferation. PLOS One. (2011) 6(2):e14716.
  30. Quinzler R., Ude M., Franzmann A., Feldt S., Schüssel K., Leuner K., Müller W.E., Dippel F.W., Schulz M. Diabetes mellitus: Persistence with basal supported oral therapy – comparison of insulin glargin versus NPH insulin. Exp. Clin. Endocrinol. Diabetes. (2012) 50(1):24
  31. Ude M., Schüssel K., Quinzler R., Leuner K., Müller W.E., Schulz M. Generic switch after ramipril patent expiryis not associated with decrease pharmacy refill compliance: a retrospective data analysis using the DAPI database. J. Hypertension. (2011) 29(9):1837-45.
  32. Kurz C., Ungerer I., Lipka U., Kirr S., Schütt T.,Eckert A., Leuner K., Müller W.E. The metabolic enhancer piracetam ameliorates ß-amyloid peptide induced impairment of mitochondrial function and neuritic outgrowth. Br. J. Pharmacol. (2010) 160(2):246-57.
  33. Leuner K., Heiser J., Derksen S., Mladenov M. I., Fehske C.J, Schubert R, Gollasch M., Schneider G., Harteneck C., Chatterjee S.S., Müller W.E. Simple 2,4 diacylphloroglucinols are specific TRPC6 activators – identification of a novel pharmacophore. Mol. Pharmacol. (2010) 77(3):368-77.
  34. Woelfle U., Laszczyk M.N., Kraus M., Leuner K., Kersten A., Simon-Haarhaus B., Scheffler A., Martin S.F., Müller W.E., Nashan D., Schempp C.M. Triterpenes promote keratinocyte differentiation in vitro, ex vivo and in vivo: A role for the transient receptor potential canolocal (subtype) 6. J. Invest. Dermatol. (2010) 130(1):113-23.
  35. Gispert S., Ricciardi F., Kurz A., Azizov M., Hoepken H.H., Becker D., Voos W., Leuner K., Müller W.E., Kudin A.P., Kunz W.S., Zimmermann A., Roeper J., Wenzel D., Jendrach M., García-Arencíbia M., Fernández-Ruiz J., Huber L., Rohrer H., Barrera M., Reichert A.S., Rüb U., Chen A., Nussbaum R.L., Auburger G. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neuro-degeneration. PLoS One. (2009) 4(6):e5777.
  36. Fehske C.J., Leuner K., Müller W.E. Ginkgo biloba extract (EGb761) influences monoaminergic neuro-transmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol. Res. (2009) 60(1):68-73.
  37. Hauptmann S., Scherping I., Dröse S., Brandt U., Schulz K.L., Jendrach M., Leuner K., Eckert A., Müller W.E. Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol. Aging. (2009) 30(10):1574
  38. Müller M., Hill K., Beschmann H., Rubant S., Boehncke W.H., Harteneck C., Müller W.E., Leuner K. Specific TRPC6 channel activation, a novel approach to stimulate keratinocyte differentiation. J. Biol. Chem. (2008) 283(49):33942-54.
  39. Becker B., Müller M., Bereiter-Hahn J., Leuner K., Jendrach M. The C-terminal cytoplasmatic domain of TRPV4 is essential for plasma membrane localization Mol. Membr. Biol. (2008) 25(2):139-51
  40. Leuner K., Kazanski V., Müller M., Essin K., Henke B., Gollasch M., Harteneck C., Müller W.E. Hyperforin - a key constituent of St. John's wort specifically activates TRPC6 channels. FASEB J. (2007) 21(14):4101-1
  41. Copanaki E., Schürmann T., Eckert A., Leuner K., Müller W.E., Prehn J.H.M., Kögel D. The Amyloid Precursor Protein potentiates CHOP induction and cell death in response to ER Ca2+ depletion. Biochim. Biophys. Acta. (2007) 1773(2):157-65.
  42. Abdel-Kader R., Hauptmann S., Keil U., Scherping I., Leuner K., Eckert A., Müller W.E. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol. Res. (2007) 56(6):493
  43. Treiber K., Singer A., Henke B., Müller W.E. Hyperforin activates non-selective cation channels. Br. J Pharmacol. (2005) 145(1):75−83.
  44. Holoubek G., Nöldner M., Treiber K., Müller W.E. Effect of chronic antidepressant treatment on beta-receptor coupled signal transduction cascade. Which effect matters most? Pharmacopsychiatry. (2004) 37 Suppl 2:S113

Peer Reviewd Reviews

  1. Stockburger C., Eckert S., Eckert G.P., Friedland K., Müller W.E. Mitochondrial Function, Dynamics, and Permeability Transition: A Complex Love Triangle as A Possible Target for the Treatment of Brain Aging and Alzheimer's Disease. (2018) J Alzheimers Dis. doi: 10.3233/JAD-179915.
  2. Müller W.E., Eckert A., Eckert G.P., Fink H., Friedland K., Gauthier S., Hoerr R., Ihl R., Kasper S., Möller H.J. Therapeutic efficacy of the Ginkgo special extract EGb761® within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease. (2017) World J Biol Psychiatry. 2:1-17. doi: 10.1080/15622975.2017.1308552.
  3. Friedland K., Harteneck C. Hyperforin - to be or not to be an activator of TRPC(6) Rev Physiol, Biochem, Pharmacol. (2015) 169:1-24
  4. Grimm A., Friedland K., Eckert A. Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer's disease. Biogerontology. (2015) accepted.
  5. Denzer I., Münch G., Friedland K. Modulation of mitochondrial dysfunction in neurodegenerative diseases via activation of nuclear factor erythroid-2-related factor 2 by food-derived compounds. Pharmacol. Res. (2015) accepted.
  6. Elsholz F., Müller W.E., Harteneck C., Friedland K. Calcium – a central regulator of keratinocyte differentiation in health and disease. EJD. (2014) 24(6):650-61.
  7. Friedland-Leuner K., Stockburger C., Denzer I., Eckert GP., Müller W.E. Mitochondrial dysfunction: cause and consequence of Alzheimer's disease. Prog Mol Biol Transl Sci. (2014) 127:183-210.
  8. Leuner K., Müller W.E., Reichert A.S. From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. Mol Neurobiol. (2012) 46(1):186-93
  9. Müller W.E., Heiser J., Leuner K. Effects of the standardized Ginkgo biloba extract EGb 761® on neuroplasticity. Int Psychogeriatr. (2012) Suppl 1:S21-4.
  10. Eckert G.P., Renner K., Eckert S.H., Eckmann J., Hagl S., Abdel-Kader R.M., Kurz C., Leuner K., Muller W.E. Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease. Mol Neurobiol. (2012) 46(1):136-50.
  11. Müller W.E., Eckert A., Kurz C., Eckert GP, Leuner K. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer’s disease – therapeutic effects. Mol. Neurobiol. (2010) 41(2-3):159-71.
  12. Leuner K., Kurz C., Guidetti G., Orgogozo J.M., Müller W.E. Improved mitochondrial function in brain aging and Alzheimer disease – the new mechanism of action of the old metabolic enhancer piracetam. Front. Neuropharmacol. (2010) 4:pii 44.
  13. Leuner K., Hauptmann S., Abdel-Kader R., Scherping I., Keil U., Strosznajder J.B., Eckert A., Müller W.E. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer’s disease? Antioxid. Redox. Signal. (2007) 9(10):1659-75
  14. Leuner K., Pantel J., Frey C., Schindowski K., Schulz K., Wegat T., Maurer K., Eckert A., Müller W.E. Enhanced apoptosis, oxidative stress and mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimer's disease. J. Neural. Transm. (2007) Suppl. 72:207-15.
  15. Leuner K., Müller W.E. The complexity of the dopaminergic synapses and their modulation by antipsychotics. Pharmacopsychiatry. (2006) 39 Suppl 1:S15-20.
  16. Leuner K., Müller W.E. Dopamine in the prefrontal cortex and its different modulation by conventional and atypical Antipsychotics. Pharmacopsychiatry. (2007) 40 Suppl 1:S2-16.Fortbildungsartikel

Other literature

  1. Friedland K., Schlager H., Schmiedel K. Typ 2 Diabetes – Prävention in Apotheken wirkt. PZ (2015) 14: 24-26
  2. Dircks M, Grömer T, Kornhuber J, Rose O, Derendorf H, Dörje F, Friedland K. Eine Patientin mit Zwangserkrankung. DAZ (2014) 154(42):432-41.
  3. Dircks M, Schmid K, Koczian U, Dörje F, Leuner K. Arzneimittelbezogene Probleme identifizieren – Ein Leitfaden. DAZ (2013) 153(38):65-69.
  4. Leuner K., Müller WE, Wolf C., Pauly A., Antipsychotika – Risiken bei älteren Patienten. PZ (2013) 158(33):2838-2848.
  5. Leuner K., Müller WE, Pauly A., Wolf C. Antipsychotika – Berechtigte Indikationen. PZ (2013)  158(33):2562-2569.
  6. Dircks M., Fuchs F., Leuner K., Dörje F., Derendorf H. Ein COPD Patient. DAZ (2013) 13: 42 ff.
  7. C., Ude M., Leuner K. Nitrates and PDE5 inhibitors – pharmaceutical care. Pharm. Unserer Zeit. (2010) 39(5):397-404.
  8. Ude M., Hengstler S., Schulz M., Müller W.E., Leuner K. Minerals and trace elements - a case for discussion Unserer Zeit. (2009) 38(3):268-76.
  9. Griese N., Hengstler S., Leuner K., Schulz M., Müller W.E. Selbstmedikation bei Depression – Der Apotheker als Lotse. Pharmazeutische Zeitung (2009) Ausgabe 13.
  10. Müller W.E., Abdel-Kader R.M., Fehske C.J., Leuner K. Grundlagen der therapeutischen Anwendung von EGb 761. Wirkung auf die Kraftwerke der Zellen. Unserer Zeit. (2009 ) 38(5):408-416.
  11. Leuner K., Müller W.E. Trizyklika als Co-Analgetika. Unserer Zeit. (2008) 37(3):220-5.
  12. Schüssel K., Leuner K., Müller W.E., Schulz M. Persistenz und Compliance bei Antihypertensiva. Pharmazeutische Zeitung (2007) Ausgabe 14.
  13. Wegat T., Metzmann K., Leuner K., Müller W.E. Antacids and H2 antihistaminics for hyperacidity. Unserer Zeit. (2007) 6(1):44-51.
  14. Wegat T., Leuner K., Müller W.E. Pharmakologie der Antidementiva: Mit viel Know-how gegen das Vergessen. Hausarzt (2007) 44(7): 66-68.
  15. Leuner K., Müller W.E. Koanalgetika hemmen das afferente Schmerzsystem. Hausarzt (2006) 11(43):54-57.

Book chapters

  1. Friedland K., Harteneck C. Spices and odorants as TRP channel activators – smell, taste, chemesthesis and beyond. Handbook of odor. Released 2015.
  2. Harteneck C. and Leuner K. TRP Channels in Neuronal and Glial Signal Transduction, Neurochemistry, Dr. Thomas Heinbockel (Ed.) (2014) ISBN: 978-953-51-1237-2, InTech, DOI: 10.5772/58232.
  3. Treiber K., Müller W.E. Effects on transmitter uptake and their cellular and molecular basis. St. John’s wort and its active principles in depression and anxiety, Milestones in Drug Therapy, Birkhäuser, 2005.


Rose O. und Friedland K.

„Angewandte Pharmakotherapie“, Deutscher Apotheker Verlag, Erscheinungsdatum 11/2014

Herausgeberin gemeinsam mit Olaf Rose

Mit folgenden eigenen Kapiteln:

  • Unipolare Depression
  • Bipolare Störung
  • Alzheimer Demenz
  • Schlafstörungen gemeinsam mit Oliver Schwalbe und Isabel Waltering
  • Diabetes mellitus Typ 2 gemeinsam mit Karin Schmiedel
Veröffentlicht am | Veröffentlicht in Publications